Clinical Trial Update: Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluates aprepitant for preventing chemotherapy-induced vomiting in children and adolescents undergoing remission induction therapy fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• EMEND (aprepitant)

Snippet

Sponsor: Dr Atul Sharma | Conditions: Chemotherapy Induced Vomiting, Acute Myeloid Leukemia | Phase 3 | Status: UNKNOWN